An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases
收藏DataCite Commons2025-01-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008220/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label, single centre, Phase I study to determine the brain exposure of
[11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
提供机构：
Vivli
创建时间：
2022-07-06
